Autolus Therapeutics PLC Sponsored ADR (NASDAQ:AUTL) Given Consensus Recommendation of "Moderate Buy" by Brokerages

Key Points

• Analysts maintain a “Moderate Buy” consensus on Autolus Therapeutics, with four buys, two strong buys, one hold and one sell among eight analysts. The average 12-month price target is $10.00, significantly above the stock’s recent $1.94 price.
• Autolus reported quarterly adjusted earnings of -$0.15 per share, beating the consensus estimate of -$0.21, while revenue of $45.69 million exceeded expectations of $38.56 million. Analysts expect a full-year loss of approximately $0.75 per share.
• Institutional investors and hedge funds own 72.83% of the shares, with several investors increasing their positions. The stock has traded between $1.18 and $2.58 over the past year and currently has a market capitalization of about $516 million.

Shares of Autolus Therapeutics PLC Sponsored ADR (NASDAQ:AUTL - Get Free Report) have received a consensus rating of "Moderate Buy" from the eight analysts that are currently covering the stock, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation, four have issued a buy recommendation and two have given a strong buy recommendation to the company. The average 1 year target price among brokerages that have issued a report on the stock in the last year is $10.00.

AUTL has been the topic of several research analyst reports. Weiss Ratings upgraded shares of Autolus Therapeutics from a "sell (e+)" rating to a "sell (d-)" rating in a research report on Thursday, August 13th. Wall Street Zen upgraded shares of Autolus Therapeutics from a "sell" rating to a "hold" rating in a research note on Sunday, August 16th. Finally, HC Wainwright reissued a "buy" rating and set a $10.00 price objective on shares of Autolus Therapeutics in a report on Monday, August 3rd.

Institutional Trading of Autolus Therapeutics

Several large investors have recently modified their holdings of the business. GAMMA Investing LLC grew its holdings in Autolus Therapeutics by 115.6% in the second quarter. GAMMA Investing LLC now owns 15,499 shares of the company's stock valued at $25,000 after purchasing an additional 8,309 shares during the period. Waverly Advisors LLC purchased a new stake in Autolus Therapeutics during the 1st quarter worth $37,000. R Squared Ltd increased its holdings in Autolus Therapeutics by 48.4% in the 1st quarter. R Squared Ltd now owns 39,575 shares of the company's stock valued at $55,000 after purchasing an additional 12,915 shares in the last quarter. SmartHarvest Portfolios LLC raised its position in Autolus Therapeutics by 177.0% in the first quarter. SmartHarvest Portfolios LLC now owns 59,185 shares of the company's stock valued at $82,000 after purchasing an additional 37,820 shares during the period. Finally, Caitong International Asset Management Co. Ltd lifted its stake in shares of Autolus Therapeutics by 55.1% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 44,053 shares of the company's stock worth $88,000 after purchasing an additional 15,647 shares in the last quarter. 72.83% of the stock is currently owned by institutional investors and hedge funds.

Autolus Therapeutics Stock Performance

Shares of Autolus Therapeutics stock opened at $1.94 on Friday. The firm's fifty day simple moving average is $1.95 and its 200-day simple moving average is $1.69. Autolus Therapeutics has a 12 month low of $1.18 and a 12 month high of $2.58. The stock has a market capitalization of $516.35 million, a price-to-earnings ratio of -1.83 and a beta of 2.10. The company has a debt-to-equity ratio of 1.04, a current ratio of 4.89 and a quick ratio of 4.40.

Autolus Therapeutics (NASDAQ:AUTL - Get Free Report) last issued its quarterly earnings results on Tuesday, August 11th. The company reported ($0.15) earnings per share for the quarter, topping the consensus estimate of ($0.21) by $0.06. The firm had revenue of $45.69 million during the quarter, compared to the consensus estimate of $38.56 million. Autolus Therapeutics had a negative return on equity of 178.66% and a negative net margin of 238.66%. As a group, equities analysts forecast that Autolus Therapeutics will post -0.75 earnings per share for the current year.

About Autolus Therapeutics

Autolus Therapeutics plc NASDAQ: AUTL is a biopharmaceutical company developing and commercializing programmed T-cell therapies for cancer and other serious diseases. The company uses genetic engineering to create CAR T-cell products designed to recognize and eliminate cancer cells while improving control, persistence and safety compared with earlier-generation cell therapies.

Autolus' lead product, obecabtagene autoleucel, also known as obe-cel and marketed in the United States as AUCATZYL, is a CD19-directed autologous CAR T-cell therapy.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.